(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.22%) $77.99
(5.65%) $2.15
(0.02%) $2 310.10
(-0.16%) $26.79
(0.37%) $966.20
(-0.35%) $0.929
(-1.07%) $10.87
(-0.11%) $0.797
(0.36%) $91.45
Live Chart Being Loaded With Signals
KemPharm, Inc., a specialty pharmaceutical company, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States...
Stats | |
---|---|
今日成交量 | 64 126.00 |
平均成交量 | 229 541 |
市值 | 200.47M |
EPS | $-0.404 ( 2023-09-29 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -6.38 |
ATR14 | $0.270 (4.65%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-10-10 | Mcfarlane Neil F. | Buy | 600 000 | Stock Option (right to buy) |
2023-10-10 | Mcfarlane Neil F. | Buy | 200 000 | Restricted Stock Unit |
2023-10-10 | Mcfarlane Neil F. | Buy | 0 | |
2023-09-05 | Schafer Joshua | Buy | 500 | Common Stock |
2023-09-06 | Clifton R. Laduane | Buy | 1 000 | Common Stock |
INSIDER POWER |
---|
97.06 |
Last 89 transactions |
Buy: 4 356 177 | Sell: 72 592 |
音量 相关性
KemPharm Inc 相关性 - 货币/商品
KemPharm Inc 财务报表
Annual | 2022 |
营收: | $10.46M |
毛利润: | $10.12M (96.72 %) |
EPS: | $-1.200 |
FY | 2022 |
营收: | $10.46M |
毛利润: | $10.12M (96.72 %) |
EPS: | $-1.200 |
FY | 2021 |
营收: | $28.65M |
毛利润: | $0.00 (0.00 %) |
EPS: | $-2.15 |
FY | 2020 |
营收: | $13.29M |
毛利润: | $11.98M (90.18 %) |
EPS: | $-3.21 |
Financial Reports:
No articles found.
KemPharm Inc
KemPharm, Inc., a specialty pharmaceutical company, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company utilizes its Ligand Activated Therapy technology to generate improved prodrug versions of FDA-approved drugs, as well as to generate prodrug versions of existing compounds that may have applications for new disease indications. Its prodrug product candidate pipeline is focused on the high need areas of attention deficit hyperactivity disorder, stimulant use disorder, and CNS rare diseases, including idiopathic hypersomnia (IH). The company's lead product candidate KP1077 which is under Phase II clinical trial for the treatment of IH and narcolepsy, is based on its prodrug of d-methylphenidate, known as serdexmethylphnidate. It is also developing KP879, a prodrug product candidate for the treatment of stimulant use disorder and is under Phase I clinical trial. In addition, the company has received FDA approval for AZSTARYS, a new once-daily treatment for attention deficit hyperactivity disorder in patents age six years and older, and for APADAZ, an immediate-release combination product containing benzhydrocodone, a prodrug of hydrocodone, and acetaminophen. KemPharm, Inc. has collaboration and license agreement, with KVK-Tech, Inc. and Commave Therapeutics SA. The company was incorporated in 2006 and is headquartered in Celebration, Florida.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。